| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.046 | 0.2 |
| mRNA | BRD-A94377914 | CTRPv2 | pan-cancer | AAC | 0.058 | 0.2 |
| mRNA | AICAR | GDSC1000 | pan-cancer | AAC | -0.043 | 0.2 |
| mRNA | JQ-1 | CTRPv2 | pan-cancer | AAC | 0.041 | 0.2 |
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | 0.04 | 0.2 |
| mRNA | CIL55A | CTRPv2 | pan-cancer | AAC | -0.064 | 0.2 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.047 | 0.2 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | 0.041 | 0.2 |
| mRNA | VER-155008 | CTRPv2 | pan-cancer | AAC | 0.046 | 0.2 |
| mRNA | NU-7441 | GDSC1000 | pan-cancer | AAC | 0.046 | 0.2 |